Michael Linden, M.D., Ph.D.
Preferred method of contact: Email
MMC 609 Mayo
420 Delaware St SE
Minneapolis, MN 55455
Dr. Linden is an Assistant Professor in the Division of Hematopathology within the Department of Laboratory Medicine and Pathology. In addition, he is the Assistant Director of the Special Hematology Laboratory. As a graduate student, Dr. Linden’s thesis work helped develop a new mouse model of multiple myeloma. Dr. Linden completed residency and fellowship training in Hematopathology at the University of Washington. He now attends on the University of Minnesota Medical Center’s Hematopathology and Flow Cytometry services. Dr. Linden continues to have a strong interest in plasma cell neoplasms and enjoys research that applies his clinical skills to improving clinical laboratory diagnoses and predicting clinical outcomes. More specifically, he is investigating optimum diagnostic methods for monitoring residual disease in myeloma patients and developing diagnostic tests to predict chemotherapeutic sensitivity of the neoplastic plasma cells. Additional clinical and research interests include pathologic correlates of outcome in marrow transplantation and comparative pathology (murine and canine). Finally, he greatly values resident/fellow education and mentorship.
- Saint Mary’s University, Winona, MN (1998), B.A. (Biology)
- University of Minnesota, Minneapolis, MN (2006), M.D., Ph.D. (Medical Scientist Training Program)
- University of Washington Medical Center, Seattle, WA (2006-2010), Residency (Anatomical and Clinical Pathology)
- University of Washington Medical Center, Seattle, WA (2010-2011), Fellowship (Hematopathology)
Board Certification (American Board of Pathology)
- Anatomic and Clinical Pathology, 2010
- Hematology, 2011
- Academy of Clinical Laboratory Physicians and Scientists (ACLPS)
- American Society for Clinical Pathology (ASCP)
- American Society of Hematology (ASH)
- College of American Pathologists (CAP)
- Society for Hematopathology and European Association for Hematopathology (SH-EAHP)
- United States and Canadian Academy of Pathology (USCAP)
Service to national organizations:
- Program and Finance Committee, Academy of Clinical Laboratory Physicians and Scientists, 2013-Present
- Diagnostic Immunology Resource Committee, College of American Pathologists, 2013-Present
- Standards Committee, College of American Pathologists, Appointed for 2014
- CTSI Office of Discovery and Translation Grant Recipient (Principal investigator), 2013
- MCC Hematologic Malignancy Innovations Award (Co-Investigator), 2013
- Resident Distinguished Teaching Award in Clinical Pathology, 2012
- Institute of Human Genetics Seed Grant Recipient (Co-Investigator), 2012
- Certificate of Excellence (top 5% of all reviewers for Laboratory Investigation), 2011
- J. Jacob Kaplan Research Award, 2006
- J. Thomas Livermore Research Award, 2004
- University of Minnesota Medical School Advanced Admissions Program Acceptance, 1996
- CRC Press Freshman Chemistry Award, 1995
Selected Invited Lectures
- "Integrated laboratory diagnosis of plasma cell neoplasms – a morphologic, genetic, and flow cytometric approach." American Society of Clinical Pathology national meetings, Boston, MA and Chicago, IL - 2012, 2013
- "Immunophenotypic features of bortezomib-resistant plasma cells toward personalized therapy in plasma cell myeloma." Saint Mary’s University, Department of Biology, Bioseminar, Winona, MN - 2013
- "Laboratory diagnosis of plasma cell neoplasms." East Metro Multiple Myeloma Patient Support Group, Stillwater, MN - 2012
- "Laboratory diagnosis of plasma cell dyscrasias and paraproteinemia associated disorders." Vanderbilt University Medical Center, Department of Pathology, Special Seminar, Nashville, TN - 2011
- "Laboratory diagnosis of plasma cell dyscrasias and paraproteinemia associated disorders." University of California-Davis Department of Pathology and Laboratory Medicine Grand Rounds, Sacramento, CA - 2010
- Editorial board of Applied Immunohistochemistry & Molecular Morph. 2013-Present
- Editorial board of Laboratory Investigation 2013-Present
- Assistant editor (Hematology Section), Lab Medicine 2012-Present
- Editorial board of the Open Journal of Blood Diseases 2012-Present
- Intern, Laboratory Investigation editorial internship program, 2009-2013
Ad hoc reviewer for:
- British Journal of Hematology
- Experimental Hematology
- Turkish Journal of Hematology
Linden MA, Ward J, and Cherian S. The Hematopoietic System. In: Comparative Anatomy and
Histology for the Translational Pathologist: A Mouse and Human Atlas, Dintzis S and Treuting
P., ed. Elsevier Press, Maryland Heights, MO, 2011.
Selected Peer Reviewed (or Refereed Journals) Publications Most Relevant to Research Focus
- Stessman HA, Mansoor A, Linden MA, Van Ness BG, and Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. PLoS One (in press)
- Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB and Van Ness BG. Reduced CXCR4 expression predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia. (in press)
- Stessman HA, Mansoor A, Linden MA, Van Ness BG, and Baughn LB. Stabilization of AID by bortezomib in a Burkitt lymphoma cell line. Leukemia and Lymphoma (in press).
- Conway A, Kaufman SC, Rudrapatna V, and Linden MA. Crystalizing immunoglobulin presenting as polychromatic crystalline keratopathy; an unusual clinical presentation of monoclonal gammopathy of undetermined significance (MGUS). Lab Medicine (in press).
- Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, and Van Ness BG. Gene signatures predict response to proteasome inhibitors and identify potential secondary therapies in a murine myeloma model. Molecular Cancer Therapeutics 2013 Jun;12(6):1140-50.
- Singh C, Yohe S, Baughn L, and Linden MA. Utility of flow cytometry to classify abnormal plasma cell populations in marrow samples collected from patients with putative plasma cell neoplasms. Open Journal of Blood Diseases 2012 Sep; 2(3): 39-45.
- Linden MA, Kirchhof N, Carlson CS, Van Ness BG. Targeted overexpression of an activated N-ras gene results in B- and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia. Experimental Hematology. 2012 Mar; 40(3):216-27.
- Linden MA, Kirchhof N, Kvitrud M, and Van Ness BG. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in bcl-XL transgenic mice. Leukemia Research. 2005 Apr; 29(4):435-444.
- Cheung WC, Kim JS, Linden MA, Van Ness BG, Polakiewicz R, Janz S. Novel targeted deregulation of c-myc and bcl-XL causes plasma cell neoplasms in mice. J Clinical Investigation. 2004 Jun; 13(12):1763-73.
- Linden MA, Kirchhof N, Carlson CS, Van Ness BG. Targeted overexpression of bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood. 2004 Apr 1; 03(7):2779-86.
- Croonquist PA, Linden MA, Zhao F, Van Ness BG. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and co-culture with bone marrow stromal cells. Blood. 2003 Oct 1; 102(7): 2581-92.
- Liu X, Linden M, Van Ness B. Induced kappa receptor editing shows no allelic preference in a mouse pre-B cell line. J Immunol. 2000 Dec 15; 165(12): 7058-63.
For a more comprehensive list of publications, please see Google Scholar.